Clinical trials: Cancer Neck
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL
The purpose of this research study is to test the safety and effectiveness of the investigational study vaccine, called TVGV-1. The study will test the vaccine in women with high grade HPV cervical infection.
- Trial name
- NCT02576561
- Testing
- TVGV-1, GPI-0100
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- THEVAX Genetics Vaccine
Squamous Cell Carcinoma of the Head and Neck
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and…
- Trial name
- NCT04034225
- Testing
- SNS-301, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Breast Cancer, Colorectal Cancer
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma
- Trial name
- FAPrimo (NCT05784597)
- Testing
- [68Ga]Ga-OncoFAP administration
- Where
- 5 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Philogen S.p.A.
Uterine Cervical Neoplasms
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.
- Trial name
- NCT02866006
- Testing
- BVAC-C, Topotecan
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Cellid Co., Ltd.
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase)…
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Trial name
- SPICE (NCT02636036)
- Testing
- enadenotucirev, nivolumab
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Akamis Bio
Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
- Trial name
- NCT00116909
- Testing
- OSI 7904L
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- OSI Pharmaceuticals
Cervical Cancer
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the…
- Trial name
- NCT04806945
- Testing
- HLX10, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Larynx Cancer
Clinical Feasibility of New Tracheoesophageal Puncture Set
During a total laryngectomy a puncture is created in the tracheoesophageal wall and a voice prosthesis is inserted. With this voice prosthesis the patient learns to speak again.
- Trial name
- NCT01045057
- Testing
- Puncture Set and Flexible Protector
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 27 people
- Sponsor
- Atos Medical AB
Thyroid Cancer
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid…
- Trial name
- EXAM (NCT00704730)
- Testing
- XL184
- Where
- 113 sites in United States, Austria and 22 more
- Volunteers
- 330 people
- Sponsor
- Exelixis
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
- Trial name
- VELOCITY-HNSCC (NCT06727565)
- Testing
- Domvanalimab, Zimberelimab, Paclitaxel
- Where
- 23 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Head and Neck Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel…
- Trial name
- NCT00971867
- Testing
- Paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
The purpose of this Chinese extension study is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in…
- Trial name
- NCT03881111
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 20 sites in China
- Sponsor
- Merck Sharp & Dohme LLC
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Thyroid Neoplasms
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
- Trial name
- NCT00389441
- Testing
- AG-013736
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Cervical Cancer
AK104 in Neoadjuvant Treatment of Cervical Cancer
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
- Trial name
- NCT05227651
- Testing
- AK104
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Akeso
Breast Cancer, Ovarian Cancer
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
- Trial name
- NCT07524322
- Testing
- RGT-490
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regor Pharmaceuticals Inc.
Advanced Cancer, Metastatic Cancer
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
This study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118.
- Conditions
- Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT03440437
- Testing
- FS118, Paclitaxel
- Where
- 12 sites in United States, France
- Volunteers
- 80 people
- Sponsor
- invoX Pharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.